Return to the catalog
Thymosin alpha-1
NewIn Stock10mg vial

Thymosin alpha-1

Natural thymic peptide studied for balanced immune responses and T-cell development.

For Research Use Only

Sold strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical/diagnostic application.

1–4 vialsR 850.00
5+ vials — save 20%R 680.00 each

The lower price is applied automatically once your cart holds 5 or more of this vial.

Bacteriostatic water included

99%+ Purity
Extensively Researched
1

About this peptide

Thymosin alpha-1 is a naturally occurring peptide made up of 28 amino acids and associated with the thymus, an organ involved in immune development. Researchers study how it influences T cells and the signals used by the immune system to recognise and respond to threats. Work also examines how it may help balance early and longer-term immune responses.

Why researchers reach for Thymosin alpha-1

T-cell maturation

Referenced in thymocyte differentiation studies.

TLR pathway

Modulates TLR2 and TLR9 signaling in vitro.

Immune balance

Adjusts Th1/Th2/Treg profiles in preclinical models.

Key features

  • ≥99% HPLC purity
  • Acetylated 28-mer thymic peptide
  • Mass-spec verified
  • Cold-chain dispatch

How it works

TLR engagement

Acts as TLR agonist on dendritic cells.

NK-cell activity

Enhances natural-killer cytotoxicity markers in vitro.

Cytokine tuning

Shifts IFN-γ, IL-2, and IL-10 expression.

Research dosage guidelines

Reference ranges only — reproduced from published preclinical literature. Not a recommendation for human use.

RangeReported doseNote
Typical reconstitution2 mL bacteriostatic waterYields 5 mg/mL (5000 mcg/mL)
Reported research range0.8–1.6 mg, 1–2× weeklyReference only

Tracking this compound? Registered researchers can log active Thymosin alpha-1 protocols in their private Research Log.

Timing in research protocols

Twice weekly, spaced evenly; no time-of-day or meal relationship reported.

  • Phase 3 trials and approved labelling specify 1.6 mg subcutaneously or intramuscularly twice weekly.
  • Course lengths of 6 months (hepatitis B) and up to 12 months in combination regimens are documented.
  • The twice-weekly interval reflects duration of immunomodulatory action, not circadian factors.
  • Responses continued to develop after courses were completed, which is why the literature uses long courses rather than short ones.

Drawn from published research protocols and pharmacology literature. Reference information for laboratory research only — not an instruction or guidance for use.

Technical specifications

Sequence
Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN
Molecular weight
3108.3 g/mol
Purity
≥99% (HPLC)
Form
Lyophilized powder
Vial size
10 mg
Storage (lyophilised vial)
Cool, dry and protected from light
Storage (after reconstitution)
2–8°C

Published research

Peer-reviewed literature on Thymosin alpha-1. Links open in a new tab.

Research use notice

Sold for in vitro laboratory research only. Not for human or veterinary use, diagnosis, or therapy.

#immunomodulator#thymic#TLR

Cart (0)

Your cart is empty